Get started
Author

Abdi Naficy

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
2020 · Milagritos D Tapia, Samba O Sow, et al. · The Lancet Infectious Diseases · 74
PDF
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia
2023 · Fadima C. Haidara, Ama Umesi, et al. · New England Journal of Medicine · 45
PDF
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
2023 · Agnes Mwakingwe-Omari, Nicolas Lecrenier, et al. · Human Vaccines & Immunotherapeutics · 39
PDF
Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers
2021 · Milagritos D. Tapia, Samba O. Sow, et al. · New England Journal of Medicine · 35
PDF
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein
2024 · Carly M. Bliss, Raffael Nachbagauer, et al. · EBioMedicine · 18
No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial
2024 · Abdi Naficy, Adrienne Kuxhausen, et al. · Human Vaccines & Immunotherapeutics · 17
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study
2025 · Robert W Frenck, Abdi Naficy, et al. · The Lancet · 16
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial
2023 · Abdi Naficy, Adrienne Kuxhausen, et al. · Clinical Infectious Diseases · 8
PDF
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial
2025 · Abdi Naficy, Yashpal Chugh, et al. · Vaccine · 1
Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age
2025 · Abdi Naficy, Mireille Venken, et al. · Open Forum Infectious Diseases
PDF
Works count: 11
Citation count: 253
H-index: 8
I10-index: 7
Year
Topic
Type